JPH11503415A - インターフェロン−τを用いる自己免疫疾患の処置方法 - Google Patents
インターフェロン−τを用いる自己免疫疾患の処置方法Info
- Publication number
- JPH11503415A JPH11503415A JP8527814A JP52781496A JPH11503415A JP H11503415 A JPH11503415 A JP H11503415A JP 8527814 A JP8527814 A JP 8527814A JP 52781496 A JP52781496 A JP 52781496A JP H11503415 A JPH11503415 A JP H11503415A
- Authority
- JP
- Japan
- Prior art keywords
- ifnτ
- ovifnτ
- treatment
- eae
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.哺乳動物被験体における自己免疫疾患を処置するための薬物の製造のための τ-インターフェロン(IFNτ)の使用であって、該処置が薬学的有効量の該薬物 を該被験体に経口投与することによる、使用。 2.前記自己免疫疾患が多発性硬化症である、請求項1に記載の使用。 3.前記IFNτがヒツジIFNτおよびウシIFNτからなる群から選択される、請求 項1に記載の使用。 4.前記IFNτがヒツジIFNτ(OvIFNτ)である、請求項3に記載の使用。 5.前記OvIFNτが配列番号2として示される配列を有する、請求項4に記載の 使用。 6.前記IFNτが組換え生産されるIFNτである、請求項1に記載の使用。 7.前記哺乳動物被験体がヒト被験体である、請求項1に記載の使用。 8.前記薬学的有効量が1日当たり約1×105単位のIFNτと約1×108単位のIFN τとの間を含む、請求項1に記載の使用。 9.前記薬学的有効量が1日当たり約1×106単位のIFNτと約1×107単位のIFN τとの間を含む、請求項8に記載の使用。 10.前記投与がさらに第2の自己免疫疾患処置薬剤の投与を包含する、請求項 1に記載の使用。 11.前記第2の薬剤がコルチコステロイド薬物である、請求項10に記載の使 用。 12.IFNτによる処置に応答性の疾患を処置するための薬物の製造のためのτ- インターフェロン(IFNτ)の使用であって、該処置が該薬物を哺乳動物被験体 に経口投与することによる、使用。 13.前記疾患が自己免疫疾患である、請求項12に記載の使用。 14.前記自己免疫疾患が多発性硬化症である、請求項13に記載の使用。 15.前記IFNτがヒツジIFNτおよびウシIFNτからなる群から選択される、請 求項12に記載の使用。 16.前記IFNτが組換え生産されるIFNτである、請求項12に記載の使用。 17.前記被験体がヒト被験体である、請求項12に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/406,190 | 1995-03-16 | ||
US08/406,190 US5906816A (en) | 1995-03-16 | 1995-03-16 | Method for treatment of autoimmune diseases |
PCT/US1996/003472 WO1996028183A1 (en) | 1995-03-16 | 1996-03-15 | Method for treatment of autoimmune diseases using interferon-tau |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007228360A Division JP2007314579A (ja) | 1995-03-16 | 2007-09-03 | インターフェロン−τを用いる自己免疫疾患の処置方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11503415A true JPH11503415A (ja) | 1999-03-26 |
JP4121553B2 JP4121553B2 (ja) | 2008-07-23 |
Family
ID=23606916
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52781496A Expired - Fee Related JP4121553B2 (ja) | 1995-03-16 | 1996-03-15 | インターフェロン−τを用いる自己免疫疾患の処置方法 |
JP2007228360A Pending JP2007314579A (ja) | 1995-03-16 | 2007-09-03 | インターフェロン−τを用いる自己免疫疾患の処置方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007228360A Pending JP2007314579A (ja) | 1995-03-16 | 2007-09-03 | インターフェロン−τを用いる自己免疫疾患の処置方法 |
Country Status (12)
Country | Link |
---|---|
US (2) | US5906816A (ja) |
EP (1) | EP0814831B1 (ja) |
JP (2) | JP4121553B2 (ja) |
KR (1) | KR100417485B1 (ja) |
AT (1) | ATE219373T1 (ja) |
AU (1) | AU688214B2 (ja) |
CA (1) | CA2214490A1 (ja) |
DE (2) | DE69621918D1 (ja) |
DK (1) | DK0814831T3 (ja) |
ES (1) | ES2177780T3 (ja) |
PT (1) | PT814831E (ja) |
WO (1) | WO1996028183A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2004058295A1 (ja) * | 2002-12-26 | 2006-04-27 | 第一アスビオファーマ株式会社 | 類天疱瘡治療剤 |
JP2007509958A (ja) * | 2003-10-31 | 2007-04-19 | ペプジェン コーポレイション | 医薬におけるインターフェロン−τの使用 |
JP2007528407A (ja) * | 2004-03-10 | 2007-10-11 | ペプジェン コーポレイション | インターフェロン−タウを含む薬剤組成物 |
JP2007314579A (ja) * | 1995-03-16 | 2007-12-06 | Univ Of Florida | インターフェロン−τを用いる自己免疫疾患の処置方法 |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6372206B1 (en) * | 1989-03-02 | 2002-04-16 | University Of Florida | Orally-administered interferon-TAU compositions and methods |
US7790153B2 (en) | 1994-04-12 | 2010-09-07 | Research Development Foundation | Method of treating rheumatoid arthritis using orally administered type one interferons |
AU5689898A (en) | 1996-12-05 | 1998-06-29 | University Of Florida | Il-10 and tgf-beta for treating autoimmune disease |
US6833256B1 (en) | 1999-06-22 | 2004-12-21 | University Of Maryland | Interferon tau mutants and methods for making them |
EP1212364A1 (en) * | 1999-08-27 | 2002-06-12 | University Of Florida | MATERIALS AND METHODS FOR INHIBITION OF IgE PRODUCTION |
AU783208B2 (en) * | 1999-12-09 | 2005-10-06 | Novartis Vaccines And Diagnostics, Inc. | Method for administering a cytokine to the central nervous system and the lymphatic system |
US20050118137A1 (en) * | 2000-07-19 | 2005-06-02 | Chih-Ping Liu | Method of treatment using interferon-tau |
US20050201981A1 (en) * | 2004-03-10 | 2005-09-15 | Chih-Ping Liu | Method of optimizing treatment with interferon-tau |
US7431920B2 (en) * | 2000-07-19 | 2008-10-07 | Pepgen Corporation | Method of treating IL-10 deficiency |
US20050084478A1 (en) * | 2000-10-17 | 2005-04-21 | Chih-Ping Liu | Combination therapy using interferon-tau |
US20040247565A1 (en) * | 2000-07-19 | 2004-12-09 | Chih-Ping Liu | Method of treatment using interferon-tau |
US7083782B2 (en) * | 2000-07-19 | 2006-08-01 | Pepgen Corporation | Method of treatment using interferon-tau |
CA2427194A1 (en) * | 2000-11-03 | 2002-05-10 | Biomedicines, Inc. | Method for short-term and long-term drug dosimetry |
WO2003063573A2 (en) * | 2001-11-09 | 2003-08-07 | Intarcia Therapeutics, Inc. | Method for treating diseases with omega interferon |
EP1455812A4 (en) * | 2001-11-26 | 2006-03-22 | Chiron Corp | TREATMENT OF ANTI-CD40 MONOCLONAL ANTIBODY FOR THE TREATMENT OF MULTIPLE SCLEROSIS |
EP1476191A2 (en) * | 2002-01-16 | 2004-11-17 | Pepgen Corporation | Oral administration of interferon-tau |
US20040037809A1 (en) * | 2002-06-28 | 2004-02-26 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of interferon beta |
US20040126360A1 (en) * | 2002-10-09 | 2004-07-01 | Manning Mark C. | Oral formulations for proteins and polypeptides |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
TW200518768A (en) * | 2003-11-17 | 2005-06-16 | Pepgen Corp | Methods for treatment of obesity and for promotion of weight loss |
US20060078942A1 (en) * | 2004-03-10 | 2006-04-13 | Pepgen Corporation | Method of treatment using interferon-tau |
US20060134750A1 (en) * | 2004-03-10 | 2006-06-22 | Pepgen Corporation | Method of treatment using interferon-tau |
US20080025948A1 (en) * | 2004-03-10 | 2008-01-31 | Chih-Ping Liu | Methods of Treatment Using Interferon-Tau |
CA2486822A1 (en) * | 2004-03-19 | 2005-09-19 | Great Neck Saw Manufacturers, Inc. | Folding utility knife |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
US20070025963A1 (en) * | 2005-07-27 | 2007-02-01 | Chih-Ping Liu | Methods for reduction of scar tissue formation |
CN101912836B (zh) * | 2005-10-21 | 2012-11-21 | 武藏工业株式会社 | 液体材料排出装置 |
US20070243163A1 (en) * | 2006-02-17 | 2007-10-18 | Chih-Ping Liu | Respiratory tract delivery of interferon-tau |
JP5143131B2 (ja) | 2006-05-30 | 2013-02-13 | インターシア セラピューティクス,インコーポレイティド | 浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ |
PL2359808T3 (pl) | 2006-08-09 | 2013-10-31 | Intarcia Therapeutics Inc | Osmotyczne systemy dostawcze i zespoły tłokowe |
US20090035273A1 (en) * | 2006-08-18 | 2009-02-05 | Pepgen Corporation | Combination treatment method with interferon-tau |
CA2683610C (en) | 2007-04-23 | 2013-01-08 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
DK2240155T3 (da) | 2008-02-13 | 2012-09-17 | Intarcia Therapeutics Inc | Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler |
WO2010142017A1 (en) | 2009-06-09 | 2010-12-16 | Defyrus, Inc . | Administration of interferon for prophylaxis against or treatment of pathogenic infection |
KR101823699B1 (ko) | 2009-09-28 | 2018-01-30 | 인타르시아 세라퓨틱스 인코포레이티드 | 실질 항정상태 약물 전달의 신속 확립 및/또는 종결 |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
MX2017015504A (es) | 2015-06-03 | 2018-05-15 | Intarcia Therapeutics Inc | Sistemas de colocacion y remoción de implante. |
AU2017268161B2 (en) | 2016-05-16 | 2020-03-12 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
AU2018206539A1 (en) | 2017-01-03 | 2019-07-18 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA878295B (en) * | 1986-11-06 | 1988-05-03 | Amarillo Cell Culture Co. Inc. | Treatment of immuno-resistant disease |
JPH02255925A (ja) * | 1988-11-30 | 1990-10-16 | Hitachi Ltd | メモリテスト方法および装置 |
US4997646A (en) * | 1989-02-23 | 1991-03-05 | University Of Florida Research Foundation, Inc. | Use of interferons of the alpha family to enhance fertility in mammals |
AU5183490A (en) * | 1989-03-02 | 1990-09-26 | University Of Florida | Composition for the inhibition of tumors and for the non-cytotoxic inhibition of replication of viruses |
US5906816A (en) * | 1995-03-16 | 1999-05-25 | University Of Florida | Method for treatment of autoimmune diseases |
US5372808A (en) * | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
CN1090510A (zh) * | 1992-10-30 | 1994-08-10 | 佛罗里达大学 | 干扰素-τ组成物及其用途 |
CA2114168A1 (en) * | 1993-03-05 | 1994-09-06 | Zlatko Dembic | Chimeric human interferon-gamma-receptor/immunoglobulin polypeptides |
EP0752880A4 (en) * | 1994-04-08 | 2000-08-09 | Brigham & Womens Hospital | TREATMENT OF AUTOIMMUNE DISEASES BY ORAL TOLERATION AND / OR INTERFERON OF TYPE I |
IL113280A (en) * | 1994-04-12 | 2004-12-15 | Res Dev Foundation | A preparation for the treatment of self-immunization diseases with the help of interferon of one type |
-
1995
- 1995-03-16 US US08/406,190 patent/US5906816A/en not_active Expired - Fee Related
-
1996
- 1996-03-15 ES ES96911300T patent/ES2177780T3/es not_active Expired - Lifetime
- 1996-03-15 CA CA002214490A patent/CA2214490A1/en not_active Abandoned
- 1996-03-15 DE DE69621918A patent/DE69621918D1/de not_active Expired - Lifetime
- 1996-03-15 DK DK96911300T patent/DK0814831T3/da active
- 1996-03-15 DE DE69621918T patent/DE69621918T4/de not_active Expired - Lifetime
- 1996-03-15 PT PT96911300T patent/PT814831E/pt unknown
- 1996-03-15 AU AU54223/96A patent/AU688214B2/en not_active Ceased
- 1996-03-15 WO PCT/US1996/003472 patent/WO1996028183A1/en active IP Right Grant
- 1996-03-15 EP EP96911300A patent/EP0814831B1/en not_active Expired - Lifetime
- 1996-03-15 JP JP52781496A patent/JP4121553B2/ja not_active Expired - Fee Related
- 1996-03-15 KR KR1019970706338A patent/KR100417485B1/ko not_active IP Right Cessation
- 1996-03-15 AT AT96911300T patent/ATE219373T1/de not_active IP Right Cessation
-
1999
- 1999-05-25 US US09/318,202 patent/US6060450A/en not_active Expired - Fee Related
-
2007
- 2007-09-03 JP JP2007228360A patent/JP2007314579A/ja active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007314579A (ja) * | 1995-03-16 | 2007-12-06 | Univ Of Florida | インターフェロン−τを用いる自己免疫疾患の処置方法 |
JPWO2004058295A1 (ja) * | 2002-12-26 | 2006-04-27 | 第一アスビオファーマ株式会社 | 類天疱瘡治療剤 |
JP2007509958A (ja) * | 2003-10-31 | 2007-04-19 | ペプジェン コーポレイション | 医薬におけるインターフェロン−τの使用 |
JP2007528407A (ja) * | 2004-03-10 | 2007-10-11 | ペプジェン コーポレイション | インターフェロン−タウを含む薬剤組成物 |
Also Published As
Publication number | Publication date |
---|---|
PT814831E (pt) | 2002-11-29 |
ATE219373T1 (de) | 2002-07-15 |
JP4121553B2 (ja) | 2008-07-23 |
WO1996028183A1 (en) | 1996-09-19 |
DE69621918D1 (de) | 2002-07-25 |
DE69621918T2 (de) | 2003-02-13 |
EP0814831A1 (en) | 1998-01-07 |
KR19980702930A (ko) | 1998-09-05 |
DE69621918T4 (de) | 2004-07-15 |
DK0814831T3 (da) | 2002-09-30 |
CA2214490A1 (en) | 1996-09-19 |
AU688214B2 (en) | 1998-03-05 |
AU5422396A (en) | 1996-10-02 |
US5906816A (en) | 1999-05-25 |
EP0814831B1 (en) | 2002-06-19 |
KR100417485B1 (ko) | 2004-03-19 |
US6060450A (en) | 2000-05-09 |
ES2177780T3 (es) | 2002-12-16 |
JP2007314579A (ja) | 2007-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11503415A (ja) | インターフェロン−τを用いる自己免疫疾患の処置方法 | |
US7214367B2 (en) | Orally-administered interferon-tau compositions and methods | |
JP3798426B2 (ja) | 自己免疫疾患の治療におけるil−12およびil−12アンタゴニストの使用 | |
Boissier et al. | Biphasic effect of interferon‐γ in murine collagen‐induced arthritis | |
Brok et al. | Interferon-gamma prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice. | |
Bocci | Roles of interferon produced in physiological conditions. A speculative review. | |
WO1997033607A9 (en) | Orally-administered interferon-tau compositions and methods | |
JP2796388B2 (ja) | G−csfの精製方法 | |
US20210244789A1 (en) | Compositions and methods for treatment of intracellular damage and bacterial infection | |
JP2014237663A (ja) | 炎症および/または内毒素ショックの治療 | |
US5780027A (en) | Methods of treatment of down syndrome by interferon antagonists | |
JPH07507567A (ja) | インスリン依存性糖尿病の予防または治療のためのil−10の使用 | |
TW200800247A (en) | Method of treatment using interferon-τ | |
JP2007528407A (ja) | インターフェロン−タウを含む薬剤組成物 | |
Manni et al. | Psoriasis induced by infliximab in a patient suffering from Crohn's disease | |
CA2543485A1 (en) | Use of interferon-tau in medicine | |
Starkebaum | Use of colony-stimulating factors in the treatment of neutropenia associated with collagen vascular disease | |
US7790153B2 (en) | Method of treating rheumatoid arthritis using orally administered type one interferons | |
JPH02304100A (ja) | ブタの肺炎または関連細菌病の予防または治療に使用するためのインターフェロン | |
Bazer | Reproductive biology of domestic animals: linkages with veterinary and human medicine | |
JP2928608B2 (ja) | インスリン依存型糖尿病予防または治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060627 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060908 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061023 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061226 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070515 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070813 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20071009 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20071122 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080411 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080430 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110509 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |